These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 23041051)
1. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin. van Jaarsveld MT; Blijdorp IC; Boersma AW; Pothof J; Mathijssen RH; Verweij J; Wiemer EA Eur J Cancer; 2013 Jan; 49(2):345-51. PubMed ID: 23041051 [TBL] [Abstract][Full Text] [Related]
2. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Ma JJ; Chen BL; Xin XY Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744 [TBL] [Abstract][Full Text] [Related]
3. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways. Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949 [TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways]. Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944 [TBL] [Abstract][Full Text] [Related]
6. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661 [TBL] [Abstract][Full Text] [Related]
7. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076 [TBL] [Abstract][Full Text] [Related]
8. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
9. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139 [TBL] [Abstract][Full Text] [Related]
10. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Asselin E; Mills GB; Tsang BK Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739 [TBL] [Abstract][Full Text] [Related]
11. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells. Jiang L; Luo RY; Yang J; Cheng YX Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441 [TBL] [Abstract][Full Text] [Related]
12. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753 [TBL] [Abstract][Full Text] [Related]
14. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor. Zhang Y; Wang J; Xiang D; Wang D; Xin X Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261 [TBL] [Abstract][Full Text] [Related]
15. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer]. Liu GY; Qu QX; Mi RR; Qi J Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932 [TBL] [Abstract][Full Text] [Related]
16. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro. Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892 [TBL] [Abstract][Full Text] [Related]
17. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness. Pavan S; Olivero M; Corà D; Di Renzo MF Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474 [TBL] [Abstract][Full Text] [Related]
18. Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells. Kim JW; Sahm H; You J; Wang M Anticancer Res; 2010 Jul; 30(7):2577-81. PubMed ID: 20682985 [TBL] [Abstract][Full Text] [Related]
19. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268 [TBL] [Abstract][Full Text] [Related]
20. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Clark DE; Errington TM; Smith JA; Frierson HF; Weber MJ; Lannigan DA Cancer Res; 2005 Apr; 65(8):3108-16. PubMed ID: 15833840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]